CADL Candel Therapeutics
Price Chart
Executive Summary
Candel Therapeutics reported Q1 2026 EPS of -$0.54, a 65.6% miss vs consensus of -$0.33, with no revenue. The company highlighted progress toward a BLA submission for aglatimagene in prostate cancer in Q4 2026, a planned pivotal phase 3 NSCLC trial initiation in June 2026, and a cash runway into Q1 2028. The EPS miss is significant for a pre-revenue biotech, but the clinical and regulatory catalysts dominate the narrative.
Actionable Insight
The EPS miss is notable but typical for a pre-revenue biotech investing heavily in clinical and commercial readiness. The stock will trade on upcoming catalysts: AUA data presentation (May 15-18), NSCLC phase 3 initiation (June 2026), and BLA submission (Q4 2026). Monitor for any safety or efficacy signals from the AUA presentation that could derail or accelerate the BLA timeline.
Key Facts
- Q1 2026 EPS of -$0.54 vs consensus -$0.33 (65.6% miss)
- No revenue reported (pre-revenue clinical-stage company)
- Cash and cash equivalents of $194.8M as of March 31, 2026, sufficient into Q1 2028
- BLA submission for aglatimagene in localized prostate cancer planned for Q4 2026
- Pivotal phase 3 NSCLC trial of aglatimagene expected to initiate in June 2026
- Extended survival tail data from phase 2a NSCLC trial reported (50% of per-protocol patients surviving beyond 24 months)
- Commercial partnership with EVERSANA announced for potential U.S. launch of aglatimagene
- $100M royalty funding agreement with RTW Investments, contingent on FDA approval
- Net loss of $8.9M in Q1 2026 vs net income of $7.4M in Q1 2025, driven by change in fair value of warrant liabilities
Financial Impact
EPS miss of $0.21 vs consensus; net loss of $8.9M; cash burn rate ~$16.3M/quarter in operating expenses
Risk Factors
- BLA submission or FDA approval may be delayed or denied
- Phase 3 NSCLC trial may fail to meet endpoints
- Cash burn rate may increase, requiring additional financing before Q1 2028
- Royalty funding agreement with RTW is contingent on FDA approval
- Competition from other oncolytic virus and immunotherapy platforms
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3294901 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 2, 2026
12d ago
|
Press Release
| $8.42 $8.80 | ▲ +4.51% | ▲ +5.21% | $8.56 (+1.66%) |
|
May 15, 2026
4w ago
|
Press Release
| $7.90 $7.66 | ▼ −3.04% | ▼ −2.39% | $8.56 (+8.35%) |
|
May 14, 2026
4w ago
|
8-K
| $8.91 $8.77 | ▼ −1.57% | ▼ −0.34% | $8.56 (−3.93%) |
|
May 14, 2026
4w ago
|
Press Release
| $8.91 $8.77 | ▼ −1.57% | ▼ −0.34% | $8.56 (−3.93%) |
|
May 4, 2026
5w ago
|
Press Release
| $7.53 $7.67 | ▲ +1.86% | ▲ +1.06% | $8.56 (+13.68%) |
|
Apr 29, 2026
6w ago
|
Press Release
| $6.18 $6.18 | · 0.00% | ▼ −1.02% | $8.56 (+38.51%) |
|
Mar 17, 2026
12w ago
|
Press Release
| $5.17 $5.04 | ▼ −2.51% | ▼ −1.12% | $8.56 (+65.57%) |
|
Mar 12, 2026
13w ago
|
8-K
| $4.98 $4.67 | ▼ −6.22% | ▼ −5.63% | $8.56 (+71.89%) |
|
Mar 12, 2026
13w ago
|
Press Release
| $4.98 $4.67 | ▼ −6.22% | ▼ −5.63% | $8.56 (+71.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access